Recruiting

Testing a new cell-based treatment for acute stroke

Plain-English translation of NCT07371624 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a treatment called , which is made from special cells (called mesenchymal stromal cells) derived from fat tissue. The goal is to find out whether is safe to give to people who have recently had an ischemic stroke (a stroke caused by a blood clot), and whether it can help them recover. Researchers will compare the medication to a placebo (a harmless dummy treatment) to see if it actually works.

Ischemic stroke is a serious medical emergency that can cause lasting disability. Currently, treatment options are limited, and doctors are searching for new therapies that might help the brain heal and restore lost function. This medication is based on promising early research suggesting that special cells may help repair brain damage after a stroke.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have had an ischemic stroke confirmed by CT or MRI scan within the past 36 hours
your stroke symptoms are moderate in severity (a specific score range on a standard stroke assessment)
you are willing to give informed consent and participate in all study visits and assessments

You likely don't qualify if…

you have already received clot-busting medication (thrombolysis) or mechanical thrombectomy for this stroke
you have a serious underlying brain condition like a tumor, brain malformation, or history of severe head injury
you have a severe infection or fever at the time of enrollment
you have serious heart, lung, liver, or kidney disease that is not well controlled
you have a positive test for hepatitis B, hepatitis C, syphilis, or HIV

What participation looks like

If you qualify, you will receive a single injection of the medication (or placebo) through an IV while you are in the hospital, within 36 hours of your stroke. After that, you will come back to the hospital for scheduled follow-up visits to have blood tests, brain scans, and neurological exams to check whether the treatment is safe and whether it is helping you recover. The trial will involve a small group of about 54 participants total, and you may be assigned to receive either the active medication or a placebo.

AI-generated summary from trial data · Aug 28, 2026 · Not medical advice

Trial locations(1 site)

China

Beijing Tiantan Hospital, Capital Medical University, Beijing